---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-25-000223"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:27:09.908389+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# BioVie appoints Amy Chappell and Kameel Farag to Board of Directors

## Summary
- Board expanded from 4 to 6 members; appointments effective July 17, 2025.
- Dr. Chappell: 25 years at Eli Lilly, led CNS drug development including Cymbalta; former CMO of Eliem Therapeutics.
- Mr. Farag: former CFO of Aspen Neuroscience (raised $150M+), SVP Finance at Ionis, Regional CFO at Amgen.
- BioVie advancing bezisterim Phase 2 trials for early Parkinson's (SUNRISE-PD) and long COVID (ADDRESS-LC).

## SEC filing metadata
- accession: 0001520138-25-000223
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/0001520138-25-000223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/bivi-20250722_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-25-000223
- JSON: https://secwatch.observer/filing/0001520138-25-000223.json
- Plain text: https://secwatch.observer/filing/0001520138-25-000223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.